09:52 AM EST - Revive Therapeutics Ltd. : announced today that the initiation of a Phase 2a proof of concept study of REV-001 (tianeptine), for the prevention of opioid-induced respiratory depression, is well underway. The study is being conducted at the Leiden University Medical Center in The Netherlands. Revive Therapeutics Ltd.
shares V.RVV are trading unchanged at $0.50.
